Johnson, E.M.

patient response outcome treatment study gmi trends baseline trend galactomannan aspergillosi value disease ia patients week 12 analysis antifungal therapy baseline gmi cohort p fizer aspergillu 12 weeks survival antifungal therapy trial serum ⌬ gmibaseline ¡w 2 weeks result week 1 week 2 gmibaseline signi signi ficant diagnosis probability group fi ndings antifungal treatment infection cutoff treatment response mortality ficant point cell transplant recipients index difference neutropenia ⌬ gmiw 1¡w responder aspergillosis study baseline gmis ⌬ gmi gilead sciences p value hematological condition gmi values likelihood nding research amphotericin b trial drug course jcm.asm.org specimen hematological endpoint number multivariate health increase maerten laboratory speci voriconazole university nonresponder cancer estimation equation